LON:ROQ Roquefort Therapeutics (ROQ) Share Price, News & Analysis → Elon to Transform U.S. Economy? (From Porter & Company) (Ad) Free ROQ Stock Alerts GBX 4.40 0.00 (0.00%) (As of 05/3/2024 ET) Add Compare Share Share Today's Range 4.30▼ 4.4050-Day Range 4▼ 9.2552-Week Range 3.90▼ 9.50Volume24,200 shsAverage Volume309,177 shsMarket Capitalization£5.68 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsHeadlinesInsider TradesStock AnalysisChartCompetitorsHeadlinesInsider Trades Get Roquefort Therapeutics alerts: Email Address Ad Stansberry ResearchGlobal crypto currency reset (41 major banks signed up)Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project... Here's everything you need to know. About Roquefort Therapeutics Stock (LON:ROQ)Roquefort Therapeutics plc, a biotechnology company, engages in the development of medicines for the treatment of cancer. The company's pre-clinical development pipeline comprises Midkine antibodies with significance in vivo efficacy and toxicology studies; Midkine RNA therapeutics with novel anti-cancer gene editing action; Midkine mRNA therapeutics with novel anti-cancer approach; STAT-6 siRNA therapeutics targeting solid tumors with significance in vivo efficacy; and MK cell therapy with direct and NK-mediated anti-cancer action. Roquefort Therapeutics plc was incorporated in 2020 and is based in London, the United Kingdom.Read More ROQ Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ROQ Stock News HeadlinesApril 26, 2024 | lse.co.ukEARNINGS AND TRADING: Aura confident in Tiris; Cindrigo enters GermanyApril 5, 2024 | msn.comUK Stocks: Here’s Why Roquefort (ROQ) Share Price is CrashingMay 4, 2024 | Awesomely, LLC (Ad)Automatic Income (from home)For over 22 years, Wall Street elites have kept this little-known "income hack" from everyday investors… 6 simple clicks have set up HUGE payouts for "in-the-know" investors… Delivering them passive income 365 days a year. March 11, 2024 | lse.co.ukRoquefort celebrates "significant milestones" in cancer researchMarch 11, 2024 | uk.investing.comRoquefort Therapeutics reveals progress with liver and colorectal cancer programmesDecember 21, 2023 | seekingalpha.comNBSE NeuBase Therapeutics, Inc.November 6, 2023 | lse.co.ukRoquefort Therapeutics MK cell programme shows positive resultsSeptember 27, 2023 | proactiveinvestors.comRoquefort Therapeutics preparing targets for clinic as eyes commercial dealsMay 4, 2024 | Awesomely, LLC (Ad)Automatic Income (from home)For over 22 years, Wall Street elites have kept this little-known "income hack" from everyday investors… 6 simple clicks have set up HUGE payouts for "in-the-know" investors… Delivering them passive income 365 days a year. September 27, 2023 | proactiveinvestors.comRoquefort Therapeutics preparing targets for clinic as it eyes commercial dealsAugust 17, 2023 | finance.yahoo.comRoquefort Therapeutics seeks to lock in future value with anti-cancer therapeutic patentsAugust 9, 2023 | finance.yahoo.comRoquefort Therapeutics making headway with siRNAJune 29, 2023 | proactiveinvestors.comRoquefort Therapeutics highlights significant progress at AGMJune 22, 2023 | proactiveinvestors.comRoquefort Therapeutics hails significant pre-clinical resultsJune 22, 2023 | marketwatch.comRoquefort Therapeutics Makes Progress on Cancer TreatmentJune 16, 2023 | finance.yahoo.comRoquefort Therapeutics returns to the market with new study dataJune 13, 2023 | marketwatch.comRoquefort Therapeutics' Anti-Cancer MRNA Study Showed Positive ResultsJune 7, 2023 | marketwatch.comRoquefort Therapeutics Resumes Trading After Publishing 2022 ResultsJune 5, 2023 | proactiveinvestors.comRoquefort Therapeutics eyes second half progressMarch 13, 2023 | proactiveinvestors.comRoquefort Therapeutics has no exposure to SVBMarch 8, 2023 | proactiveinvestors.comRoquefort Therapeutics says new mRNA platform "fits very well"March 8, 2023 | proactiveinvestors.comRoquefort develops a fifth programme using a technology pioneered by Moderna and BioNTechMarch 6, 2023 | proactiveinvestors.comRoquefort Therapeutics establishes scientific advisory boardFebruary 22, 2023 | lse.co.ukRoquefort Thera Regulatory NewsFebruary 21, 2023 | barrons.comRoquefort Therapeutics PLCFebruary 20, 2023 | proactiveinvestors.comRoquefort Therapeutics inks Randox diagnostic dealFebruary 20, 2023 | proactiveinvestors.comRoquefort Therapeutics inks first strategic licensing deal with diagnostics firm RandoxSee More Headlines Receive ROQ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Roquefort Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:ROQ CUSIPN/A CIKN/A Webwww.roquefortinvest.com Phone44 20 3290 9339FaxN/AEmployees9Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (0.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income£-1,740,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-27.46% Return on Assets-17.44% Debt Debt-to-Equity RatioN/A Current Ratio2.26 Quick Ratio3.07 Sales & Book Value Annual Sales£637.00 Price / Sales8,920.88 Cash FlowGBX 2.94 per share Price / Cash Flow1.49 Book ValueGBX 4 per share Price / Book1.10Miscellaneous Outstanding Shares129,150,000Free FloatN/AMarket Cap£5.68 million OptionableNot Optionable Beta-0.09 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. Stephen Paul West B.Com (Age 52)CA, Executive Chairman Comp: $118.31kMr. Trevor Ajanthan Reginald (Age 52)CEO & Executive Director Comp: $284.1kProf. Martin J. Evans FRS (Age 83)Group Chief Scientific Officer & Executive Director Comp: $101.22kDr. Emma MorrisHead of Pre-Clinical ResearchKey CompetitorsBSF EnterpriseLON:BSFAValiRxLON:VALGenflow BiosciencesLON:GENFIXICOLON:IXIOxford Cannabinoid TechnologiesLON:OCTPView All CompetitorsInsidersDr Darrin DisleyBought 269,935 shares on 8/1/2023Total: £1.89 M ($7.00/share)Stephen Paul WestBought 15,730 shares on 7/12/2023Total: £94,380.00 ($6.00/share)Stephen Paul WestBought 144,117 shares on 6/26/2023Total: £1.01 M ($7.00/share)Trevor Ajanthan (Ajan) ReginaldBought 35,265 shares on 6/23/2023Total: £246,855.00 ($7.00/share)View All Insider Transactions ROQ Stock Analysis - Frequently Asked Questions How have ROQ shares performed in 2024? Roquefort Therapeutics' stock was trading at GBX 7.25 at the beginning of 2024. Since then, ROQ stock has decreased by 39.3% and is now trading at GBX 4.40. View the best growth stocks for 2024 here. How do I buy shares of Roquefort Therapeutics? Shares of ROQ stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. This page (LON:ROQ) was last updated on 5/4/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldCould Your Accounts Be Frozen?Allegiance GoldAutomatic Income (from home)Awesomely, LLCGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingJeff Bezos Just Humiliated Elon MuskInvestorPlaceForget Nvidia. This is the future of AIPorter & CompanyThe asset beating inflation by 4xColonial Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Roquefort Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
